Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Published version of a preprint
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
H-Ras, K-Ras, and N-Ras regulate cellular growth and survival and are often activated by somatic mutation in human tumors. Although oncogenic lesions occur in a single Ras isoform within individual tumors, it is unclear whether the remaining wild-type isoforms play supporting roles in tumor growth. Here, we show that oncogenic and wild-type Ras isoforms play independent and nonredundant roles within the cell. Oncogenic Ras regulates basal effector pathway signaling, whereas wild-type Ras mediates signaling downstream of activated receptor tyrosine kinases (RTK). We show that both are necessary for exponential growth of Ras-mutant cell lines. Furthermore, we show that oncogenic Ras desensitizes signaling from EGF receptor (EGFR). Depletion of oncogenic Ras with siRNA oligonucleotides relieves this negative feedback, leading to the hyperactivation of EGFR and wild-type Ras signaling. Consistent with this model, combining oncogenic Ras depletion with EGFR inhibition potently increases cell death. Significance: The results of this study highlight a novel role for wild-type Ras signaling in cancer cells harboring oncogenic RAS mutations. Furthermore, these findings reveal that therapeutically targeting oncogenic Ras signaling alone may be ineffective owing to feedback activation of RTKs, and suggest that blocking upstream RTKs in combination with downstream effector pathways may be beneficial in the treatment of Ras-mutant tumors. Cancer Discov; 3(1); 112–23. ©2012 AACR. See related commentary by Hayes and Der, p. 24 This article is highlighted in the In This Issue feature, p. 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“this mechanism of action is unlikely to be effective against the second mechanism of adaptive feedback (RTK-driven activation of wild type RAS) (33).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [33]
In the citing paper
“Therefore, genetic depletion of oncogenic RAS with siRNA oligonucleotides relieves this negative feedback, leading to hyperactivation of EGFR and wild-type RAS signaling [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“Previous studies have shown that oncogenic RAS regulates the basal effector pathway, whereas wild-type RAS mediates signaling downstream of the activated receptor tyrosine kinases [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“WT RAS alleles have been shown to be critical in maintaining the growth and signaling of RAS-mutant cell lines, especially from extracellular signals through RTKs and flux through the MAPK pathway (Cheng et al., 2021; Young et al., 2013; Zhou et al., 2016).”
From KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy (2022) · cites this paper as Young et al., 2013
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 2×
“Oncogenic RAS alleles differ from their wild-type counterpart by a single missense point mutation that results in an amino acid substitution typically at position 12, 13, or 61 (6, 7).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 2×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Oncogenic mutation in any one of the three RAS genes is thought to be sufficient to constitutively activate downstream signaling and confer independence from upstream growth cues (8).”
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 9×
“The aberrant hyperactivation of Ras plays a causal role in human cancer, and an estimated 30% of human tumors harbor oncogenic somatic mutations in HRAS , KRAS , or NRAS ( 5, 6 ).”
InfluentialKinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
Cited by
Items 101–200 of 211
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112269 · Cited by 25
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
Mattox, T. E., Chen, X., Maxuitenko, Y. Y., Keeton, A. B., & Piazza, G. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010141 · Cited by 31
“These wild-type isoforms have been shown to drive RAS signaling independently of oncogenic RAS under certain conditions of growth factor stimulation [37].”
BackgroundSie, M., den Dunnen, W. F. A., Lourens, H. J., Boer, T. M.-D., Scherpen, F. J. G., Zomerman, W. W., Kampen, K. R., Hoving, E. W., & de Bont, E. S. J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122555 · Cited by 28
“This kinome reprogramming circumvents inhibition of proto-oncogenic kinases as for instance described for oncogenic RAS.[19] Furthermore, inhibition of specific RTKs could trigger the tumor to upregulate RTK ligands.”
BackgroundOncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells
Doubleday, P. F., Fornelli, L., Ntai, I., & Kelleher, N. L. (2021) · The FEBS Journal · doi:10.1111/febs.16111 · Cited by 23
Dimerization Opens New Avenues into Ras Signaling Research
Santos, E. (2014) · Science Signaling · doi:10.1126/scisignal.2005318 · Cited by 28
“org 6 May 2014 Vol 7 Issue 324 pe12 2 development and progression, and whether wild-type Ras contributes to oncogenic Ras–driven tumorogenicity (10, 11).”
BackgroundRas–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
Lee, H.-J., Cao, Y., Pham, V. C., Blackwood, E. R., WILSON, C. A., Evangelista, M., Klijn, C. N., Stokoe, D., & Settleman, J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0504 · Cited by 24
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall, T. B., Trogdon, M., Guizar, A. C., Langenheim, J. F., Sisk-Hackworth, L., & Stites, E. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00329-w · Cited by 29
Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
Sunaga, N., Miura, Y., Kasahara, N., & Sakurai, R. (2021) · Cancers · doi:10.3390/cancers13235956 · Cited by 25
“Oncogenic RAS upregulates downstream pathways and negatively regulates RTK signaling, whereas attenuating oncogenic RAS results in compensatory activation of RTK and wild-type RAS signaling pathways [93].”
BackgroundMilton, C. K., Self, A. J., Clarke, P. A., Banerji, U., Piccioni, F., Root, D. E., & Whittaker, S. R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1131 · Cited by 24
“Given the role of ERBB family activity in enhancing signaling through KRAS in NSCLC (67, 68), one may speculate that inhibition of mTOR, downstream of ERBB family inhibition, may result from attenuation of RTK-driven wild-type KRAS signaling (72).”
BackgroundH-Ras regulation of TRAIL death receptor mediated apoptosis
Chen, J., Bozza, W. P., Di, X. M., Zhang, Y., Hallett, W. H. D., & Zhang, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2091 · Cited by 21
SOS1 interacts with Grb2 through regions that induce closed nSH3 conformations
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0013926 · Cited by 20
KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer
Yang, Y., Sang, Z., Ma, J., Zhu, Y., & Wu, S. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2969 · Cited by 20
Ohm, A. M., Tan, A. C., Heasley, L. E., & Reyland, M. E. (2017) · Oncogene · doi:10.1038/onc.2017.27 · Cited by 20
“Similarly, McCormick and colleagues have shown that oncogenic K-Ras, but not wild type K-Ras, regulates basal ERK signaling in KRAS mutant cancer cells (45).”
Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect
Singh, S., Krishna, A., Singh, V., Kumar, V., Singh, U., & Sankhwar, S. (2018) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_246_17 · Cited by 21
“For the last two decades, it has been shown that Ras genes are frequently mutated in different types of tumor and participate in their proliferation and maintenance.[9] G12D, G12V, G13D, G13R, Q61H and Q61R are possible missense mutations occurring at codons G12, G13 and Q61; but their frequencies are not consistent.”
BackgroundDNA or not DNA —that is the question determining the design of platinum anticancer drugs
Jin, S., Feng, C., & Wang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117077 · Cited by 22
Pappa, K. I., Vlachos, G. D., Roubelakis, M. G., Vlachos, D., Kalafati, T. G., Loutradis, D., & Anagnou, N. P. (2015) · BioMed Research International · doi:10.1155/2015/303791 · Cited by 19
Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting
Michael, J. V., & Goldfinger, L. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.021 · Cited by 19
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 22
“Moreover, wild-type, but not oncogenic, RAS regulates signaling from upstream RTKs [33].”
BackgroundPanitumumab safety for treating colorectal cancer
Stremitzer, S., Sebio, A., Stintzing, S., & Lenz, H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915024 · Cited by 20
“This fact may be explained by a blockage of the inhibitory effect of RAS wt isoforms in RAS mt tumors by anti-EGFR antibodies [33].”
BackgroundAn Orthosteric Inhibitor of the RAS–SOS Interaction
Nickerson, S., Joy, S. T., Arora, P. S., & Bar‐Sagi, D. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00002-0 · Cited by 17
Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function
Hobbs, G. A., Gunawardena, H. P., Baker, R., Chen, X., & Campbell, S. L. (2013) · Small GTPases · doi:10.4161/sgtp.26270 · Cited by 17
“Ras GTPases regulate a variety of cellular functions, including gene expression, cell growth, and differentiation.(1) Although Ras proteins are part of a larger superfamily of small guanine nucleotide binding proteins, Ras is the only family member that is frequently mutated in human cancer.”
The potential of targeting Ras proteins in lung cancer
McCormick, F. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.1000304 · Cited by 17
“However, Ras cancers still retain some dependency on these signals [4]; the strength of these signals is”
BackgroundSelf-citationKaboli, P. J., Luo, S., Chen, Y., Jomhori, M., İmani, S., Xiang, S., Wu, Z., Li, M., Shen, J., Zhao, Y., et al. (2022) · Gene · doi:10.1016/j.gene.2021.146171 · Cited by 16
Haagensen, E. J., Thomas, H. D., Mudd, C., Tsonou, E., Wiggins, C. M., Maxwell, R. J., Moore, J. D., & Newell, D. R. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.012 · Cited by 17
Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies
Dubińska–Magiera, M., Migocka-Patrzałek, M., Lewandowski, D., Daczewska, M., & Jagla, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115654 · Cited by 18
“survival, inhibition of this process could explain the myotoxic mechanism of statins [31], reviewed by [8].”
BackgroundThe Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
Wan, X., Liu, R., & Li, Z. (2017) · BioMed Research International · doi:10.1155/2017/5356737 · Cited by 17
Yin, N. B., Lepp, A., Ji, Y., Mortensen, M., Hou, S., Qi, X.-M., Myers, C. R., & Chen, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779488 · Cited by 18
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
Wang, S., Li, Q., Ma, P., Fang, Y., Yu, Y., Jiang, N., Miao, H., Tang, Q., Yang, Y., Xing, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.831382 · Cited by 18
“Apart from genetic alterations associated with spontaneous tumor development, it has been increasingly appreciated that KRAS mutation also exhibits a broad impact on the tumor microenvironment, which helps to promote and maintain the malignancy of cancer (Young et al., 2013; Kortlever et al., 2017; Ambrogio et al., 20…”
BackgroundYun, C., Gang, L., Gu, R., Xu, W., Xuezhi, M., & Huanqiu, C. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22241 · Cited by 14
Weyandt, J. D., Lampson, B. L., Tang, S., Mastrodomenico, M., Cardona, D. M., & Counter, C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140253 · Cited by 15
“We chose Hras, as it is activated downstream of oncogenic Kras in PDAC cell lines [8 – 10], and of the three Ras genes, is the only one that is not embryonic lethal in a background like that of KC mice which encodes only one functional Kras allele [22].”
InfluentialMutant and wild-type Ras: co-conspirators in cancer
Hayes, T. K., & Der, C. J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0521 · Cited by 13
One Hippo and many masters: differential regulation of the Hippo pathway in cancer
Romano, D., Matallanas, D., Frederick, D. T., Flaherty, K. T., & Kölch, W. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140030 · Cited by 13
Ghosh, S., Varela, L., Sood, A., Park, B. H., & Lotan, T. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0429 · Cited by 14
“24 desensitizes upstream HER signaling and relief of this negative feedback via depletion of oncogenic RAS has the paradoxical effect of hyperactivating EGFR and wild-type RAS (40).”
InfluentialSpecific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement
Kim, S. J., Kim, J. H., Yang, B., Jeong, J., & Lee, S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.005 · Cited by 14
“This is probably due to the complexities of oncogenic KRAS-induced regulation of downstream pathways, feedback activation of receptor tyrosine kinases, or adaptability of the cancers in finding alternative signal transduction pathways to reestablish oncogenic signaling.(21,44,45) For example, knockdown of oncogenic KR…”
BackgroundInfluentialReduced HRASG12V-Driven Tumorigenesis of Cell Lines Expressing KRASC118S
Huang, L., & Counter, C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123918 · Cited by 13
“activated in cells harboring an oncogenic RAS mutation [7,23,37].”
BackgroundYorkie-Cactus (IκBα)-JNK axis promotes tumor growth and progression in Drosophila
Snigdha, K., Singh, A., & Kango-Singh, M. (2021) · Oncogene · doi:10.1038/s41388-021-01831-4 · Cited by 11
MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer
Sharma, S. B., & Ruppert, J. M. (2015) · Drug Development Research · doi:10.1002/ddr.21270 · Cited by 11
“Our analysis of GAP signaling and RAS-GTP levels in this study yielded results that were consistent with the newly emerging paradigm that the output of RAS-ERK signaling is critically dependent on the activation status of WTRAS, and uncovered a previously unappreciated role for GAP proteins in cells harboring RAS muta…”
BackgroundResultInfluentialDeepSom: a CNN-based approach to somatic variant calling in WGS samples without a matched normal
Вилов, С. А., & Heinig, M. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btac828 · Cited by 10
Werner, A. N., Kumar, A. I., & Charest, P. G. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-05-0152 · Cited by 12
“…cells harboring distinct Ras-mutant isoforms revealed the presence of a potential negative feedback loop, driven by oncogenic Ras, that desensitizes growth factor and WT Ras signaling, and that targeting oncogenic Ras can then lead to increased signaling and tumorigenicity (Young et al. , 2013).”
Kale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 12
Miller, A. L., Perurena, N., Gardner, A., Hinoue, T., Loi, P., Laird, P. W., & Cichowski, K. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0370 · Cited by 13
“For example, in some settings KRAS mutant tumors have been shown to require intact H-and/or N-RAS proteins for proliferation, growth, or survival (39 – 42), whereas in other studies the loss of wild-type H-or N-RAS enhanced KRAS tumor development (43, 44).”
New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women
Poorhosseini, S. M., Hashemi, M. M., Olyaei, N. A., Izadi, A., Moslemi, E., Ravesh, Z., Hashemi‐Gorji, F., Kheiri, H. R., & Yassaee, V. R. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.155 · Cited by 10
“, 2013), others found either a negative, or a positive (Li-Weber, 2013a), but statistically insignificant association (Young et al., 2013; Giltnane and Balko, 2014).”
Bantel, H., & Canbay, A. E. (2018) · Gut · doi:10.1136/gutjnl-2017-315630 · Cited by 10
Inhibition and degradation of NRAS with a pan-NRAS monobody
Whaby, M., Ketavarapu, G., Koide, A., Mazzei, M., Mintoo, M. J., Glasser, E., Patel, U. R., Nasarre, C., Sale, M. J., McCormick, F. P., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03186-y · Cited by 11
Self-citationMatsubara, H., Miyoshi, H., Kakizaki, F., Morimoto, T., Kawada, K., Yamamoto, T., Obama, K., Sakai, Y., & Taketo, M. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0411 · Cited by 10
Umelo, I. A., Wever, O. D., Kronenberger, P., Deun, J. V., Noor, A., Singh, K., Teugels, E., Chen, G., Bracke, M., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3853 · Cited by 9
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer
Ku, B. M., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1372196 · Cited by 11
“Examining RAS pathway rewiring with a chemically inducible activator of RAS”
Rose, J. C., Dieter, E. M., Cunningham‐Bryant, D., & Maly, D. J. (2018) · Small GTPases · doi:10.1080/21541248.2018.1446697 · Cited by 8
Stites, E. C. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/005397 · Cited by 10
“Increased wild-type Ras signaling in combination with oncogenic Ras mutants has been demonstrated multiple times by multiple groups [26, 51-55].”
BackgroundMethodInfluentialDevi, P., Dwivedi, R., Sankar, R., Jain, A., Gupta, S., & Gupta, S. (2024) · Head and Neck Pathology · doi:10.1007/s12105-024-01623-8 · Cited by 16
“Over the past two decades, there has been evidence indicating frequent mutations in Ras genes across various tumor types, highlighting their involvement in tumor proliferation and maintenance [18].”
Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice
Weyandt, J. D., Carney, J. M., Pavlisko, E. N., Xu, M., & Counter, C. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167205 · Cited by 7
Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · eLife · doi:10.7554/elife.79747 · Cited by 7
Pathan, A. A. K., Panthi, B., Khan, Z., Koppula, P. R., Alanazi, M. S., Parine, N. R., Chourasia, M., & Sachchidanand, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s99671 · Cited by 8
“This initiates multiple signaling pathways with various downstream effectors, such as the Raf kinase and phosphatidylinositol 3-kinase-related protein families.(5,6) Mutations in these regions are reported in almost all types of human cancer.”
McGregor, M., & Price, T. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0711 · Cited by 10
Kumar, S. U., & Doss, C. G. P. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104597 · Cited by 8
Safari, M. H., Rahimzadeh, P., Alaei, E., Alimohammadi, M., Esfandiari, N., Daneshi, S., Malgard, N., Farahani, N., Taheriazam, A., & Hashemi, M. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102013 · Cited by 9
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 8
“210 Conversely, in lung cancer, WT RAS suppresses mutant RAS-driven tumors via mutant-WT heterodimerization.”
Kamgar, M., Hobbs, G. A., Davidson, R., Dorbin, D., Herrera, J., Langenheim, J. F., Burge, R. A., Aldakkak, M., Conrardy, R. D., Szabó, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0018 · Cited by 12
“This finding contributes to a growing literature about WT-RAS contributing to a cancer-promoting signal (17, 28–30).”
Ferguson, R., Aughton, K., Evans, A., Shaw, V. E., Armstrong, J. A., Ware, A., Bennett, L. G., Costello, E., & Greenhalf, W. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030164 · Cited by 7
“Previous studies have shown that depleting wild-type N-Ras and H-Ras in KRas mutant cell lines reduces EGFR responsiveness [33].”
BackgroundInfluentialPanitumumab for the Treatment of Metastatic Colorectal Cancer: A Review
Prete, M. D., Giampieri, R., Faloppi, L., Bianconi, M., Bittoni, A., Andrikou, K., & Cascinu, S. (2015) · Immunotherapy · doi:10.2217/imt.15.46 · Cited by 7
Expression and Prognostic Role of MEKK3 and pERK in Patients with Renal Clear Cell Carcinoma
Chen, Q., Lu, H., Gan, M., Chen, L.-X., He, K., Fan, G., & Cao, X. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2495 · Cited by 7
Zomerman, W. W., Plasschaert, S. L. A., Diks, S. H., Lourens, H.-J., Boer, T. M.-D., Hoving, E. W., den Dunnen, W. F. A., & de Bont, E. S. J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141381 · Cited by 6
“Furthermore, various mutated or amplified cancer cell lines with kinase-dependency were able to bypass the growth-inhibitory effects of specific RTK inhibitors after addition of growth factors usually secreted by the tumor microenvironment[21 – 23].”
Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
Guo, X., Zhao, W., Liu, Z., & Wang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.24025 · Cited by 7
“The different manipulations of cell cycle to apoptosis may be attributed to the negative feedback pathways existed in the cancer cells driven by mutant KRas rather than by wildtype KRas oncogenes [26].”
BackgroundInfluentialWild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., LaMorte, J. P., Gambhir, V., Beckley, Z., Linke, A. J., Wilkerson, M. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adx5186 · Cited by 7
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer
Heinlein, M., Li, G. X., Kljavin, N. M., Moore, A. R., Biehs, B., Tao, L., Boumahdi, S., Mohammadi, F., Shi, M., Liang, Y., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01155-w · Cited by 8
“Nota-bly, lung metastases showed greater sensitivity than liver metastases, likely reflecting site-specific microenvironmental cues such as growth factors that may modulate WNT 41,42 and MAPK signaling 43 despite underlying mutations in these pathways.”
Discoveries in the redox regulation of KRAS
Kramer‐Drauberg, M., & Ambrogio, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105901 · Cited by 6
Beatty, J. S., Molnar, C., Luque, C. M., de Celis, J. F., & Martin-Bermudo, M. D. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009738 · Cited by 7
“Thus, even though oncogenic Ras isoforms are constitutively active, EGFR activation can induce GTP loading on wild type Ras isoforms, enhancing effector pathway signaling [62].”
BackgroundCofré, J., & Saalfeld, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1067248 · Cited by 8
“It is also worth mentioning the relevant and well-recognized role of the non-mutated protein (wild-type Ras) in promoting exponential growth in cancer cell models (T24, MIA PaCa-2, and RD cell lines), whose effects within the cell are non-redundant and independent from those of mutated Ras isoforms (Young et al., 2013…”
BackgroundZhong, L., Meng, X., Huang, J., Hao, W., & Zuo, Y. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-97 · Cited by 7
The end of KRAS, and other, cancers? A new way forward
Mallucci, L., & Wells, V. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.018 · Cited by 6
Hussain, J., Chhabria, D., & Kirubakaran, S. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127290 · Cited by 5
Yuan, Y., Sun, X., Liu, M., Li, S., Dong, Y., Hu, K., Zhang, J., Xu, B., Ma, S., Jiang, H., et al. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023111 · Cited by 6
“Kras is a crucial downstream effector of RTK signaling and serves as a critical clinical indicator for cetuximab therapy response in CRC [45].”
Role of silent mutations in KRAS-mutant tumors
Lu, J. G., Zhou, C., Pan, F., Liu, H., Jiang, H., Zhong, H., & Han, B. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003405 · Cited by 6
Wang, H., Moniruzzaman, R., Li, L., Ji, B., Liu, Y., Zuo, X., Abbasgholizadeh, R., Zhao, J., Liu, G., Wang, R. L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163873 · Cited by 4
Ilter, M., & Şensoy, Ö. (2019) · Scientific Reports · doi:10.1038/s41598-019-47481-1 · Cited by 3
Analysis of RAS as a tumor suppressorPreprint
Kenney, C., & Stites, E. C. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/153692 · Cited by 4
“Kenney C and Stites EC 8 lead to wild-type RAS activation [14, 25-29].”
BackgroundDairo, G., Ilesanmi, A., Balogun, T. A., Ward, M. N., Soendergaard, M., & Determan, J. J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2191133 · Cited by 4
“Studies have reported that p63 targets genes that promote tumor cell growth and cancer progression (Grabocka et al., 2014; Young et al., 2013).”
BackgroundSHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer ModelsPreprint
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Araki, K. Y., Simeone, D. M., Miller, G., Neel, B. G., & Tang, K. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/307876 · Cited by 3
Is This the Dawn of Precision Oncology in Head and Neck Cancer?
Pearson, A. T., & Vokes, E. E. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00569 · Cited by 3
Ivanišević, T., Magits, W., Ma, Y., Zhao, P., Boxel, E. V., Lechat, B., Stites, E. C., Velde, G. V., Sewduth, R. N., & Sablina, A. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.27.582346 · Cited by 3
Wild-Type RAS: Keeping Mutant RAS in CHK
Anastassiadis, T., & Brown, E. J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.029 · Cited by 2
“…of the growth factor signaling pathways impacted by RAS later demonstrated that wild-type (WT) RAS isoforms play a significant role in the transformative abilities of oncogenic RAS mutants (Huang et al., 1993; Lim et al., 2008; Young et al., 2013), but the molecular mechanism remained unknown.”
BackgroundCD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas
Hirsch, R. M., Droby, G. N., Premsankar, S., Parrish, M., Kurnit, K. C., Chiou, L. F., Rabjohns, E. M., Lee, H. N., Broaddus, R. R., Vaziri, C., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.189510 · Cited by 3
“The same principle applies to other major oncogenes; for example, regulators of WT Ras signaling do not always constrain oncogenic Ras mutants (37).”
New Avenue to Inhibit Ras Signaling
Bustelo, X. R. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.001 · Cited by 2
“RasWT proteins are also implicated in signaling compensatory effects elicited by anti-Ras therapies, such as the stimulation of Ras pathways caused by the loss of the MEK-mediated inhibition of the EGF receptor typically observed when using MEK inhibitors (Figure 1A, point f) (Young et al., 2013).”
BackgroundTakamoto, Y., Arima, Y., & Saya, H. (2016) · Genes to Cells · doi:10.1111/gtc.12435 · Cited by 2
Kaboli, P. J., & Ling, K. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817666200212125658 · Cited by 2
Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthPreprint
Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.08.451571 · Cited by 2
Adaptor protein Abelson interactor 1 in homeostasis and disease
Petersen, M., & Dubielecka, P. M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01738-z · Cited by 1
“KRAS activation is upstream of signaling processes directly affected by ABI1 including PI3K/AKT and Rac/ CDC42 [185, 186], and also affects MAPK cascade and NF-κB activation [187, 188].”
BackgroundProto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer
Kim, D., Sharif, S., Garay, J. A. R., Bhakta, A. S., Boland, P. M., Cavnar, M. J., Churchman, M. L., Hatoum, H. A., Huang, L. C., Kim, J., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71114 · Cited by 1
Non-canonical EGFR signaling promotes MAPK-dependent extrusion of epithelial cells
Molina, P., Daniel, M., Hoang, T., Wang, J., & Macara, I. G. (2025) · Journal of Cell Science · doi:10.1242/jcs.264173 · Cited by 1
“In other cases, activation of other endogenous, WT isoforms of Ras (H-Ras, N-Ras) by EGFR has been proposed to further stimulate the ERK pathway (Young et al., 2013).”
Luna-Ramírez, L., García‐Navas, R., Santos, E., & Baltanás, F. C. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02632-7 · Cited by 3
“In fact, RAS oncogene-driven tumor cells frequently retain an important dependence on GEF activity mediated by SOS proteins [18, 19].”
Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies
Kumar, S. S., Price, T. J., Townsend, A. R., Hocking, C. M., & Hardingham, J. E. (2014) · Colorectal Cancer · doi:10.2217/crc.14.3 · Cited by 1
Tintelnot, J., Metz, S., Trentmann, M., Oberle, A., von Wenserski, L., Schultheiß, C., Braig, F., Kriegs, M., Fehse, B., Riecken, K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01559 · Cited by 1
“(25) show that silencing of such inhibitory unmutated RAS isoforms releases signaling downstream oncogenic RAS, our”
BackgroundResultInfluentialBrandt, R., Sell, T., Lüthen, M., Uhlitz, F., Klinger, B., Riemer, P., Giesecke-Thiel, C., Schulze, S., El-Shimy, I. A., Kunkel, D., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/340844 · Cited by 1
Neural network approach to somatic SNP calling in WGS samples without a matched controlPreprint
Вилов, С. А., & Heinig, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.14.488223 · Cited by 1
“Somatic mutations that corrupt genes regulating cell growth, programmed cell death or neovascularization can promotetheformationofacancer(Li et al. ,1992;Hanahan and Weinberg, 2000; Young et al. , 2013; Gao et al. , 2014).”
BackgroundIlter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.489309 · Cited by 1
“…phosphatidylinositol 3-kinase (PI3K), and Ras-like (RAL) pathways Barbacid (1987); Malumbres and Barbacid (2003); Lu et al. (2016a); Khan et al. (2019); Duffy and Crown (2021); Simanshu et al. (2017); Ferro and Trabalzini (2010); De Luca et al. (2012); Young et al. (2013); Knight and Irving (2014).”
BackgroundTetramethylrhodamine ethyl ester perchlorate (TMRE)
Sabnis, R. W. (2015) · Wiley eBooks · doi:10.1002/9781119007104.ch142
IN THE SPOTLIGHT Mutant and Wild-type Ras: Co-conspirators in Cancer
Hayes, T. K., & Der, C. J. (2013)
Sharma, S. B. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6619
“KLF4 is present at low levels in VSMCs and normally represses the differentiation of these cells in response to TGFβ (77,94,95).”
BackgroundQuantitative Proteomics to Support Translational Cancer Research
Hoffman, M. A. (2018) · Digital Commons - University of South Florida (University of South Florida)
Role of RAS signaling in Hedgehog-associated embryonal rhabdomyosarcoma
Bauer, J. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7239
Metadata
- Authors
- Young, A., Lou, D., & McCormick, F.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Cancer Discovery
- Published
- 2013-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 112-123
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1980323101
- Semantic Scholar
- 0fc5d9d29e0913d74b3ea62adbe40a92015d90a3
- Cited by
- 211
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 18 · 2022: 13 · 2021: 14 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 18 · 2016: 14 · 2015: 24 · 2014: 23 · 2013: 15
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS wild-type, Ras isoforms, MAPK signaling, receptor tyrosine kinase, EGFR, negative feedback signaling, combination therapy, EGFR inhibition, tumor cell proliferation
- MeSH terms
- Erlotinib Hydrochloride, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Quinazolines, Genes, ras, Apoptosis, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.